Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Genxone's OCF Margin % or its related term are showing as below:
WAR:GX1'
s OCF Margin % Range Over the Past 10 Years
Min: -2243.86 Med: -113.49 Max: 48.91
Current: -82.51
During the past 8 years, the highest OCF Margin % of Genxone was 48.91%. The lowest was -2243.86%. And the median was -113.49%.
WAR:GX1's OCF Margin % is ranked worse than 51.58% of 950
companies
in the Biotechnology industry
Industry Median: -64.565
vs WAR:GX1: -82.51
Genxone OCF Margin % Related Terms
Genxone OCF Margin % Historical Data
* Premium members only.
The historical data trend for Genxone's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:GX1 vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, Genxone's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genxone OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genxone's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Genxone's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genxone (WAR:GX1) has a OCF Margin % of -65.78% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Genxone and its competitors. According to the industry distribution chart, Genxone ranks #490 out of 950 companies in the Biotechnology industry, placing it in the top 51.6%.
Is Genxone's OCF Margin % too high?
Genxone's current OCF Margin % is -65.78%. Based on the distribution chart, Genxone ranks #490 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genxone has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genxone's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genxone ranks #490 out of 950 companies for OCF Margin %. This places Genxone in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Genxone and its competitors. Genxone's current OCF Margin % is -65.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genxone stock overvalued right now?
Based on GuruFocus' analysis, Genxone (WAR:GX1) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.51, compared to a current price of zł5.68 — trading 12.7% below its estimated fair value. The current OCF Margin % is -65.78%. Genxone's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Genxone (WAR:GX1), the current OCF Margin % is -65.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genxone (WAR:GX1) Overvalued in 2026?
Based on GuruFocus' analysis, Genxone stock appears to be undervalued.
The current stock price of zł5.68 is trading 12.7% below its estimated GF Value™ of zł6.51.
GuruFocus considers Genxone to be Modestly Undervalued.
Key valuation signals for WAR:GX1:
OCF Margin %: -65.78%
GF Value™: zł6.51 vs. price of zł5.68 (12.7% below fair value)
No single metric tells the full story. See the WAR:GX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.
66GF Score
Get the complete analysis for WAR:GX1
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:GX1 has been successfully added to your 
